Kazia Therapeutics Files 6-K, Confirms 20-F Annual Reporting

TL;DR

**Kazia Therapeutics just filed a standard 6-K, confirming its 20-F annual report status.**

AI Summary

KAZIA THERAPEUTICS LTD, a foreign private issuer, filed a Form 6-K with the SEC on February 21, 2024. This report indicates that the company files annual reports under Form 20-F. The filing provides updated administrative information for the company, including its business address at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.

Why It Matters

This routine filing ensures regulatory compliance for Kazia Therapeutics, providing transparency to investors regarding its reporting obligations as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information, indicating low risk.

Key Players & Entities

• KAZIA THERAPEUTICS LTD (company) — registrant
• February 2024 (date) — month of report
• Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000 (company) — principal executive office address
• 000-29962 (company) — Commission File Number
• Form 20-F (company) — annual report type

FAQ

Filing Documents

• d775786d6k.htm (6-K) — 12KB
• d775786dex991.htm (EX-99.1) — 10KB
• 0001193125-24-040846.txt ( ) — 23KB

of the study established the maximal tolerated dose (MTD) of paxalisib in combination with radiation

Part I of the study established the maximal tolerated dose (MTD) of paxalisib in combination with radiation therapy, while also demonstrating promising signs of clinical activity in all nine evaluable patients. Part II was a follow-on expansion cohort to further evaluate safety and efficacy of the MTD (45mg daily) combined with radiation therapy in up to 12 additional patients. After reviewing the Part II patient data generated to date, the three lead investigators have determined that the primary endpoint of the study has been reached. In addition, the investigators continued to observe encouraging signs of clinical response in patients in the expansion cohort. Detailed findings from Part II of this study are slated for submission and presentation at a forthcoming global scientific meeting, where they will contribute to the ongoing conversation about treatment options for patients with these complex brain metastases. Last year, paxalisib was awarded Fast Track Designation (FTD) on the basis of the Part I clinical data by the United States Food and Drug Administration (FDA) for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Approximately 200,000 cancer patients develop brain metastases in the United States each year. Radiotherapy is the mainstay of treatment for brain metastases, and generally consists of either stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) or some combination thereof. The efficacy in patients who receive WBRT differs according to the type of tumor and the number and volume of brain metastases, but several recent publications cite overall response rates of 20-45%. The increasing incidence of brain metastasis and the low response rates to existing treatments underscores the need for new treatment options. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the

View Full Filing

View this 6-K filing on SEC EDGAR